Gongwin Biopharm Holdings Co., Ltd. (hereinafter referred to as "Gongwin-KY", stock code: 6617) just obtained the approval for its clinical research project from the Bureau of Animal and Plant Health Inspection and Quarantine, COA, Executive Yuan in the second half of November last year. Immediately, it signed the subject consent forms with the parents of their companion animals, the fury babies suffering from malignant tumor have already received the treatment of "p-toluenesulfonamide" in the cooperating animal hospitals and have been under observations for the safety and effectiveness of the drug after the administration.
"Gongwin-KY" said that as the concept of social caring for animals continues to develop, companion animals (cats/dogs) have been recognized as family members, caring for one another and sharing common living spaces. And more and more families are willing to pay huge medical expenses and invest time in home care when their companion animals suffer from major diseases. Especially after their companion animals suffering from cancer receive traditional treatments, the side effects often make parents feel distressed. Therefore, "Gongwin-KY" hopes to take advantage of the targeted tumor ablation characteristics of PTS anti-cancer drugs and invest in the development of new drugs for companion animals to meet this market trend.
"Gongwin-KY" pointed out that this approved canine research focuses on nerve sheath tumor, melanoma, bladder cancer, lipomas and other diseases, and these tumor diseases are common and tricky problems for fury babies. "Gongwin-KY" is expected to complete the research before the end of this year, marking an important milestone by striving after the huge global animal cancer treatment market.
Looking forward to the future, "Gongwin-KY" will continue to develop drugs for other common cancers in cats/dogs, and hope to bring new treatment opportunities for the highly-socialized family companion animals globally, so as to create contributions to overall operations in the future.
Keywords: new drug development, Gongwin-KY, fury babies
Pierre Hsiao, Deputy General Manager of Gongwin Biopharm